查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1964184

伴侣动物术后疼痛管理治疗市场－全球产业规模、份额、趋势、机会、预测：按动物种类、产品、给药途径、地区和竞争格局划分，2021-2031年

Companion Animal Postoperative Pain Management Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal, By Product, By Route of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球伴侣动物术后疼痛管理疗法市场预计将从 2025 年的 2.1456 亿美元成长到 2031 年的 3.4466 亿美元，复合年增长率达到 8.22%。

此领域涵盖用于缓解宠物术后急性疼痛的药品，包括非类固醇消炎剂和鸦片类药物。市场成长的主要驱动力是兽医院进行的整形外科和牙科手术数量的增加，以及动物福利临床标准的提升。此外，兽医医疗基础设施的改善和新型给药系统的引入，提高了镇痛方案的有效性，也是推动市场成长的因素。

市场概览
预测期 2027-2031
市场规模：2025年 2.1456亿美元
市场规模：2031年 3.4466亿美元
复合年增长率：2026-2031年 8.22%
成长最快的细分市场 非类固醇消炎剂（NSAIDs）
最大的市场 北美洲

饲主在宠物健康方面承担的巨大经济负担进一步推动了市场成长。根据美国宠物用品协会（APPA）统计，2024年美国兽医保健支出和产品销售额将达398亿美元。然而，儘管支出强劲，但复杂外科手术和必要的疼痛管理通讯协定的高昂费用仍然是一项重大挑战。这些费用可能会使经济拮据的饲主无法获得最佳护理，这可能会阻碍市场的进一步扩张。

市场驱动因素

伴侣动物饲养和领养率的不断提高是全球伴侣动物术后疼痛管理治疗市场的主要驱动力。随着宠物数量的增长，需要兽医护理的动物数量（包括整形外科疾病、软组织损伤和牙科问题的手术治疗）自然也在增加。这种激增直接催生了对术后止痛药物的需求，而患者数量的增加也需要增加止痛药的处方量。此外，人类与动物之间日益紧密的联繫促使饲主寻求更先进的医疗护理，以确保宠物能够获得与人类相当的疼痛缓解。根据英国宠物食品公司于2024年3月发布的《2024年宠物数据报告》，英国的宠物数量已达3,600万隻，60%的家庭拥有伴侣动物，这显着扩大了有效治疗方案的目标市场。

镇痛药的研发和药物递送系统的进步是第二个关键驱动因素，从根本上改变了临床治疗通讯协定。业界正从传统的短效鸦片类药物和非类固醇消炎剂转向长效标靶治疗，例如单株抗体。这些疗法提高了慢性疼痛和术后疼痛的安全性和药物顺从性。这些创新使兽医能够更频繁、更长时间地开立疼痛管理处方。硕腾公司（Zoetis）于2024年11月发布的2024年第三季财报清晰地展现了这一趋势，该财报显示，其用于治疗骨关节炎疼痛的单株抗体产品系列（包括利宝利（Librela）和索乐西亚（Solensia））的全球收入增长了97%。此外，该领域强劲的财务状况也为持续创新提供了支持。 2024年2月，礼来动物保健公司（Elanco Animal Health）宣布2023年全年销售额达44.17亿美元，显示该公司拥有强大的投资能力，用于开发下一代兽用治疗药物。

市场挑战

先进的外科手术及其后续疼痛管理通讯协定的高成本是全球伴侣动物术后疼痛管理药物市场成长的主要障碍。经济拮据的宠物饲主往往无力负担宠物必要的整形外科或牙科手术费用。由于术后疼痛药物的需求与手术数量直接相关，手术数量的减少会立即缩小这些药物的潜在市场规模。

因此，这种经济压力导致饲主推迟或放弃兽医治疗，从而缩小了处方笺止痛药的基本客群。近期业界数据显示兽医服务使用率下降，也印证了这个趋势。根据美国兽医学会（AVMA）的数据，2023年8月至2024年8月期间，全美动物医院的就诊量下降了2.3%。就诊量的下降表明，不断上涨的费用导致饲主不愿寻求专业医疗服务，从而减少了兽医开立和使用术后止痛药的机会。

市场趋势

全球伴侣动物术后疼痛管理市场正迅速重塑临床实践，而减少鸦片类药物的使用以及采用非鸦片类药物疗法的趋势日益显着。这一趋势的主要驱动因素是阿片类药物处方监管力度加大以及持续的供应链不稳定，这些因素威胁着受监管兽药的供应。因此，临床医师正转向多重药物合併治疗方案，优先使用非类固醇消炎剂（NSAIDs）、局部麻醉剂和α2促效剂，以确保有效镇痛的同时，最大限度地减少对全身性通讯协定类药物的依赖。供应限制凸显了这项转变的迫切性。根据美国系统药剂师协会（ASHP）2024年12月发布的药品短缺统计数据，美国共发生214起药品短缺事件，其中阿片类镇痛药的供应中断尤为严重，迫使医疗专业人员采取替代治疗策略。

同时，脂质体包裹药物技术正成为延长术后镇痛持续时间的创新方法。诸如脂质体Bupivacaine等先进製剂，只需单次局部麻醉剂即可在数天内持续释放活性成分，覆盖关键的术后72小时，无需导管或重复注射。这项技术解决了宠物依从性问题，并减轻了宠物在康復期间频繁用药的压力。投资这些专业给药平台的公司取得的商业性成功，也印证了这个市场趋势。根据礼来动物保健公司（Elanco Animal Health）于2024年11月发布的2024年第三季财报，该公司宠物保健业务营收达4.86亿美元，再次印证了其专业外科和疼痛管理产品组合（包括先进的长效疗法）的稳健财务永续性。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：伴侣动物术后疼痛管理治疗药物的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依动物种类（狗、猫、马、其他）
    • 副产品（非类固醇抗发炎药、麻醉剂、鸦片类药物、其他）
    • 给药途径（口服、注射）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美伴侣动物术后疼痛管理治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲伴侣动物术后疼痛管理治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区伴侣动物术后疼痛管理治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲伴侣动物术后疼痛管理治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美伴侣动物术后疼痛管理治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球伴侣动物术后疼痛管理治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Zoetis Inc.
  • Merck & Co., Inc.
  • Elanco Animal Health Inc.
  • Ceva Sante Animale SA
  • Boehringer Ingelheim International GmbH
  • Norbrook Laboratories
  • Dechra Pharmaceuticals PLC
  • Chanelle Pharma
  • Bimeda Holdings Limited
  • VETOQUINOL SA

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 20483

The Global Companion Animal Postoperative Pain Management Therapeutics Market is projected to expand from USD 214.56 Million in 2025 to USD 344.66 Million by 2031, achieving a compound annual growth rate of 8.22%. This sector comprises pharmaceutical agents, including non-steroidal anti-inflammatory drugs and opioids, designed to alleviate acute pain in pets following surgical interventions. The market is primarily driven by the rising volume of orthopedic and dental procedures in veterinary clinics, alongside elevated clinical standards for animal welfare. Furthermore, the growth is supported by improvements in veterinary infrastructure and the introduction of novel drug delivery systems that enhance the effectiveness of pain relief solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 214.56 Million
Market Size 2031USD 344.66 Million
CAGR 2026-20318.22%
Fastest Growing SegmentNSAIDs
Largest MarketNorth America

Significant financial commitment from pet owners regarding animal health further reinforces market progress. According to the American Pet Products Association, United States expenditure on veterinary care and product sales reached $39.8 billion in 2024. However, despite this strong spending, the high costs associated with complex surgical interventions and necessary pain management protocols pose a substantial challenge. These expenses can restrict access to optimal care for economically constrained pet owners, thereby potentially hindering broader expansion of the market.

Market Driver

Increasing rates of companion animal ownership and adoption serve as a primary catalyst for the Global Companion Animal Postoperative Pain Management Therapeutics Market. As the pet population grows, there is a natural rise in the absolute number of animals requiring veterinary care, including surgeries for orthopedic conditions, soft tissue injuries, and dental diseases. This surge generates a direct demand for postoperative pain therapeutics, as a larger patient base necessitates a higher volume of analgesic prescriptions. Additionally, the strengthening human-animal bond drives owners to seek advanced medical care, ensuring their pets receive pain relief comparable to human standards. According to the 'Pet Data Report 2024' by UK Pet Food in March 2024, the United Kingdom's pet population reached 36 million, with 60% of households owning a companion animal, significantly widening the addressable market for effective therapeutic solutions.

Advancements in analgesic drug development and delivery systems constitute a second critical driver, fundamentally reshaping clinical treatment protocols. The industry is transitioning from traditional short-acting opioids and non-steroidal anti-inflammatory drugs toward long-acting, targeted therapies such as monoclonal antibodies, which offer enhanced safety and compliance for chronic and postoperative pain. These innovations encourage veterinarians to prescribe pain management more frequently and for extended durations. This trend is highlighted by Zoetis's 'Third Quarter 2024 Financial Results' in November 2024, which reported that their monoclonal antibody portfolio for osteoarthritis pain, including Librela and Solensia, achieved 97% operational revenue growth globally. Furthermore, the sector's robust financial health supports continued innovation; Elanco Animal Health reported full-year 2023 revenue of $4.417 billion in February 2024, underscoring the significant investment capacity available for developing next-generation veterinary therapeutics.

Market Challenge

The high cost associated with advanced surgical interventions and subsequent pain management protocols represents a significant barrier to the growth of the Global Companion Animal Postoperative Pain Management Therapeutics Market. When veterinary care becomes financially prohibitive, economically constrained pet owners are often compelled to decline necessary orthopedic or dental surgeries for their animals. Since the demand for postoperative pain therapeutics is directly linked to the volume of surgical procedures performed, any reduction in surgical caseloads immediately diminishes the total addressable market for these pharmaceutical agents.

Consequently, this financial pressure forces owners to delay or abandon potential veterinary treatments, effectively contracting the customer base for prescription pain relief solutions. This trend is evident in recent industry data showing a decline in veterinary utilization. According to the American Veterinary Medical Association, data collected between August 2023 and August 2024 indicated a 2.3% decrease in patient visits across veterinary practices in the United States. This drop in engagement suggests that rising costs are causing owners to forego professional care, thereby reducing the opportunities for veterinarians to prescribe and administer postoperative analgesics.

Market Trends

The shift toward opioid-sparing and non-opioid therapeutics is rapidly redefining clinical practices within the Global Companion Animal Postoperative Pain Management Therapeutics Market. This trend is primarily driven by increasing regulatory scrutiny on opioid prescriptions and persistent supply chain instabilities that threaten the availability of controlled substances for veterinary use. As a result, clinicians are pivoting toward multimodal protocols that prioritize non-steroidal anti-inflammatory drugs (NSAIDs), local anesthetics, and alpha-2 agonists to minimize reliance on systemic opioids while ensuring effective analgesia. The urgency of this transition is highlighted by supply constraints; according to the American Society of Health-System Pharmacists (ASHP) in their December 2024 'Drug Shortages Statistics', there were 214 active drug shortages in the United States, with significant disruptions in opioid analgesics, compelling practitioners to adopt alternative therapeutic strategies.

Simultaneously, the development of liposome-encapsulated drug technologies is emerging as a transformative approach for extending the duration of postoperative pain relief. These advanced formulations, such as liposomal bupivacaine, allow for a single administration of a local anesthetic that releases the active ingredient over several days, covering the critical 72-hour post-surgical window without the need for catheters or repeated injections. This technology addresses compliance challenges and reduces the stress associated with frequent medication administration in recovering pets. The commercial success of companies investing in these specialized delivery platforms validates this market trajectory; according to Elanco Animal Health's 'Third Quarter 2024 Financial Results' in November 2024, the company reported Pet Health revenue of $486 million, reinforcing the robust financial viability of its specialized surgical and pain management portfolio which includes advanced long-acting therapeutics.

Key Market Players

  • Zoetis Inc.
  • Merck & Co., Inc.
  • Elanco Animal Health Inc.
  • Ceva Sante Animale S.A.
  • Boehringer Ingelheim International GmbH
  • Norbrook Laboratories
  • Dechra Pharmaceuticals PLC
  • Chanelle Pharma
  • Bimeda Holdings Limited
  • VETOQUINOL S.A.

Report Scope

In this report, the Global Companion Animal Postoperative Pain Management Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Companion Animal Postoperative Pain Management Therapeutics Market, By Animal

  • Dogs
  • Cats
  • Horses
  • Others

Companion Animal Postoperative Pain Management Therapeutics Market, By Product

  • NSAIDs
  • Anesthetics
  • Opioids
  • Others

Companion Animal Postoperative Pain Management Therapeutics Market, By Route of Administration

  • Oral
  • Injectable

Companion Animal Postoperative Pain Management Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Companion Animal Postoperative Pain Management Therapeutics Market.

Available Customizations:

Global Companion Animal Postoperative Pain Management Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Companion Animal Postoperative Pain Management Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal (Dogs, Cats, Horses, Others)
    • 5.2.2. By Product (NSAIDs, Anesthetics, Opioids, Others)
    • 5.2.3. By Route of Administration (Oral, Injectable)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Companion Animal Postoperative Pain Management Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal
    • 6.2.2. By Product
    • 6.2.3. By Route of Administration
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Route of Administration
    • 6.3.2. Canada Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Route of Administration
    • 6.3.3. Mexico Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Route of Administration

7. Europe Companion Animal Postoperative Pain Management Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal
    • 7.2.2. By Product
    • 7.2.3. By Route of Administration
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Route of Administration
    • 7.3.2. France Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Route of Administration
    • 7.3.3. United Kingdom Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Route of Administration
    • 7.3.4. Italy Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Route of Administration
    • 7.3.5. Spain Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Route of Administration

8. Asia Pacific Companion Animal Postoperative Pain Management Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal
    • 8.2.2. By Product
    • 8.2.3. By Route of Administration
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Route of Administration
    • 8.3.2. India Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Route of Administration
    • 8.3.3. Japan Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Route of Administration
    • 8.3.4. South Korea Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Route of Administration
    • 8.3.5. Australia Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Route of Administration

9. Middle East & Africa Companion Animal Postoperative Pain Management Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal
    • 9.2.2. By Product
    • 9.2.3. By Route of Administration
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Route of Administration
    • 9.3.2. UAE Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Route of Administration
    • 9.3.3. South Africa Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Route of Administration

10. South America Companion Animal Postoperative Pain Management Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal
    • 10.2.2. By Product
    • 10.2.3. By Route of Administration
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Route of Administration
    • 10.3.2. Colombia Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Route of Administration
    • 10.3.3. Argentina Companion Animal Postoperative Pain Management Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Companion Animal Postoperative Pain Management Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. Elanco Animal Health Inc.
  • 15.4. Ceva Sante Animale S.A.
  • 15.5. Boehringer Ingelheim International GmbH
  • 15.6. Norbrook Laboratories
  • 15.7. Dechra Pharmaceuticals PLC
  • 15.8. Chanelle Pharma
  • 15.9. Bimeda Holdings Limited
  • 15.10. VETOQUINOL S.A.

16. Strategic Recommendations

17. About Us & Disclaimer